Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Low-dose transdermal estrogen viable short-term treatment for menopausal women

20.04.2004


Alternative hormones, doses and delivery systems not explored in WHI may exhibit



Low-dose transdermal hormone therapy (HT) remains a viable short-term alternative for women to treat debilitating menopausal symptoms, offer lipid protection and preserve bone health, despite the negative news about oral HT effects from the Women’s Health Initiative (WHI), according to a recent review of peer-reviewed medical studies by Mary Jane Minkin, M.D., of Yale University School of Medicine, in the April The Journal of Reproductive Medicine.

"There is a lot to consider when interpreting the WHI results. The fact is that millions of women still suffer from the potentially devastating symptoms of menopause – so much so that their quality of life deteriorates. Hormone therapy remains the most effective means to relieve vasomotor symptoms, and certain estrogen formulations and routes of administration that were not studied in WHI offer different health effects that may offer several advantages," said Dr. Minkin, clinical professor in the Department of Obstetrics and Gynecology at Yale.


Unexpected results from the WHI published in June 2002 called into question the safety of all HTs – even though investigators only examined oral HTs that used conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA). The researchers cautioned that the WHI results did not necessarily apply to other doses of CEE/MPA, to other types of oral estrogens and progestins, or to other estrogens and progestins delivered by different routes.

"Reproductive healthcare professionals may find it difficult to counsel their patients who suffer from severe menopausal symptoms about appropriate treatment because not all estrogens and progestins are alike. Alternative drugs, doses and delivery systems may exhibit better safety profiles than CEE/MPA formulations, with no loss of efficacy," Dr. Minkin noted.

Transdermal, unlike oral, HT delivery bypasses the liver, permitting the use of estrogen doses that are substantially less than in pills, thereby reducing the risk of certain adverse effects while providing benefits, according to the review. Transdermal formulations of the transdermal estradiol (E2) offer relief of such menopausal symptoms as hot flashes, night sweats and disturbed sleep that affect patients’ quality of life.

Moreover, the use of transdermal E2 offers protection against two heart-damaging lipids by decreasing levels of low-density lipoprotein (LDL) cholesterol and triglycerides. Both lipids play a role in the development of metabolic syndrome, which becomes more common in women as they age, particularly after the onset of menopause. The syndrome is associated with an increased risk for heart disease and is a major predictor of type 2 diabetes.

"When women with the metabolic syndrome require HT for the relief of their vasomotor symptoms, transdermal E2 can provide the additional benefit of decreasing both LDL cholesterol and triglyceride levels significantly lower than those achieved with oral HTs. In fact, oral estrogen can produce an initial increase in triglycerides, before achieving moderate lipid decreases, " said Dr. Minkin.

Additionally, unlike oral CEE, which causes a substantial increase in C-reactive protein (CRP), transdermal E2 shows no increase in CRP. CRP is a sensitive marker of inflammation associated with an increased risk of heart attacks and strokes. Transdermal E2 also builds bone mass density, which could benefit women at risk for osteoporosis.

Recent guidelines issued by the American Association of Clinical Endocrinologists and the North American Menopause Society recommend the use of transdermal estrogen, rather than oral HT, for women with high triglyceride levels. The U.S. Food and Drug Administration advises women who decide that HT is appropriate to use the lowest effective dose for the shortest duration to reach their treatment goals.

Menopause
Menopause is a natural part of a woman’s life that occurs when menstruation stops permanently, on average at age 51. During menopause, the ovaries reduce their production of the hormones estrogen, progesterone and androgen.

About 75 percent of menopausal women report troublesome symptoms--which can become severely debilitating in up to 20 percent: including heart palpitations, hot flashes, night sweats, headaches, mood swings, anxiety, irritability, loss of vaginal lubrication, changes in sexual functioning, numbness, tingling, fatigue, increase in urinary problems, memory loss, weight gain and dry eyes and mouth. Also, the menopausal decline in hormone levels can have potential long-term consequences not immediately apparent, such as increased risk for osteoporosis and coronary heart disease.

Lissa Burt | EurekAlert!
Further information:
http://www.porternovelli.com/

More articles from Health and Medicine:

nachricht New study points the way to therapy for rare cancer that targets the young
22.11.2017 | Rockefeller University

nachricht Penn study identifies new malaria parasites in wild bonobos
21.11.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

Corporate coworking as a driver of innovation

22.11.2017 | Business and Finance

PPPL scientists deliver new high-resolution diagnostic to national laser facility

22.11.2017 | Physics and Astronomy

Quantum optics allows us to abandon expensive lasers in spectroscopy

22.11.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>